Dechra Pharma HY Revenue Up 15% At CER - Quick Facts

Dechra Pharmaceuticals PLC (DPH.L) reported that group net revenue for the half year period ended on 31 December 2021 increased by about 15% at constant exchange rates or 10% at actual exchange rates.

European Pharmaceuticals net revenue growth was 10% at CER in the period, including the acquisitions of Osurnia and Tri-Solfen in Australia and New Zealand. Existing net revenues increased by 8% at CER in the period.

North American Pharmaceuticals net revenue growth was 26% at CER in the period or 21% at actual exchange rates.

The company noted that outlook for the full financial year is positive and in line with the upper end of management expectations despite the continuing COVID-19 disruption. The Group results should continue to benefit from good growth in the Companion Animal market.

Dechra said it will announce its Interim Results for the Period on 21 February 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Restaurant Association or NRA has urged the U.S. Congress to refill the Restaurant Revitalization Fund or RRF, which is expected to save more than 1.6 million jobs in the restaurant industry hit hard by the surge in Omicron Variant. In a letter to Congress, the association highlighted, based on its survey on 4,200 restaurant operators, the devastating impact so far on the industry... Industrial conglomerate General Electric Co. reported Tuesday a net loss for the fourth quarter compared to a profit last year, hurt by steep debt extinguishment costs and lower revenues. However, adjusted earnings per share topped analysts' expectations, while quarterly revenues missed them. Shares of LM Ericsson were gaining more than 7 percent in Swedish trading as well as in pre-market activity on Nasdaq, after the telecom equipment maker reported Tuesday higher profit and sales in its fourth quarter with strong demand. Further, the company lifted its full-year dividend, and maintained targets for fiscal 2022 EBIT growth as well as long-term target of EBITA margin.
Follow RTT